Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nang Kuang Pharmaceutical CoTPE:1752 -1.10%88 Return-on-Tangible-Equity is 12.05% as of Dec. 2025, which is 28% above its 10-year median of 9.41. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 66.8% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nang Kuang Pharmaceutical Co's annualized net income for the quarter that ended in Dec. 2025 was NT$295 Mil. Nang Kuang Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$2,451 Mil. Therefore, Nang Kuang Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.05%.
The historical rank and industry rank for Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
TPE:1752'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.84 Med: 9.41 Max: 15.17
Current: 10.16
During the past 13 years, Nang Kuang Pharmaceutical Co's highest Return-on-Tangible-Equity was 15.17%. The lowest was 4.84%. And the median was 9.41%.
TPE:1752's Return-on-Tangible-Equity is ranked better than 66.8% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs TPE:1752: 10.16
Nang Kuang Pharmaceutical Co (TPE:1752) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Nang Kuang Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Nang Kuang Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co Return-on-Tangible-Equity Chart
TPE:1752 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.05% mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Return-on-Tangible-Equity of 12.05% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nang Kuang Pharmaceutical Co and its competitors. This is 28% above median its historical median of 9.41. Over the past decade, Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 4.84 to 15.17. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #252 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity too high?
Nang Kuang Pharmaceutical Co's current Return-on-Tangible-Equity of 12.05% is 28% above median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 4.84 to a high of 15.17. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. Nang Kuang Pharmaceutical Co's value of 12.05% is 198.3% above this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #252 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #252 out of 759 companies for Return-on-Tangible-Equity. This puts Nang Kuang Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.04. Nang Kuang Pharmaceutical Co's value of 12.05% is 198.3% above this benchmark. Historically, Nang Kuang Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 4.84 to 15.17 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 4.04, Nang Kuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current Return-on-Tangible-Equity of 12.05% is 198.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nang Kuang Pharmaceutical Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current Return-on-Tangible-Equity is 12.05%, which is 28% above median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current Return-on-Tangible-Equity is 12.05%, which is 28% above median its 10-year median of 9.41 and 198.3% above the Medical Devices & Instruments industry median of 4.04. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Return-on-Tangible-Equity is 12.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TPE:1752:
Return-on-Tangible-Equity: 12.05% (28% above median its 10-year median of 9.41)
GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
Industry Position: 198.3% above the Medical Devices & Instruments median (#252 of 759)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score
Get the complete analysis for TPE:1752
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
